A71623|cas:130408-77-4|西域试剂

A71623,99.90%

产品编号：Bellancom-P1096| CAS NO：130408-77-4| 分子式：C₄₄H₅₆N₈O₉| 分子量：840.96

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P1096	￥2950.00	杭州北京（现货）
Bellancom-P1096	￥8850.00	杭州北京（现货）
Bellancom-P1096	￥14000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

A71623

产品介绍

A71623 是一种有效且高度选择性的 CCK-A 激动剂。A-71623 对 CCK-A 和 CCK-B 的 IC₅₀ 分别为 3.7 nM 和 4500 nM。

生物活性

A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC₅₀s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively.

体外研究

In guinea pig gastric glands, the affinities of A-71623 for the cholecystokinin (CCK)-B/gastrin receptor were 11 μM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

A71623 (A-63387; i.c.v., but not i.p., injections) reduces food intakes and suppresses intakes of a liquid diet in both deprived and sated rats.
A71623 dampens Purkinje neuron pathology and associates deficits in motor performance in Pcp2-ATXN1[30Q]D776;Cck^-/- and Pcp2-AXTN1[82Q] mice.
A71623 improves motor performance of Pcp2-ATXN2[127Q] SCA2 mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male, Sprague-Dawley rats
Dosage:	5 μL
Administration:	Intracerebroventricular (i.c.v) administration, A-71623 was infused using a 28 gauge injection cannula in a volume of 5uL over 60 s
Result:	Reduced food intakes and suppressed intakes of a liquid diet.

Animal Model:	ATXN1[30Q]-D776, ATXN1[82Q]-D776, ATXN2[127Q], and WT/FVB/NJ mice
Dosage:	0.02 mg/kg/day
Administration:	Osmotic minipumps containing either A71623 (0.02mg/kg/day) were implanted intraperitoneally (i.p.)
Result:	Treatment dampened Purkinje neuron pathology in ATXN1[30Q]D776;Cck^-/- mice and ATXN1[82Q] mice. Improved motor performance in ATXN2[127Q] mice.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male, Sprague-Dawley rats
Dosage:	5 μL
Administration:	Intracerebroventricular (i.c.v) administration, A-71623 was infused using a 28 gauge injection cannula in a volume of 5uL over 60 s
Result:	Reduced food intakes and suppressed intakes of a liquid diet.

Animal Model:	ATXN1[30Q]-D776, ATXN1[82Q]-D776, ATXN2[127Q], and WT/FVB/NJ mice
Dosage:	0.02 mg/kg/day
Administration:	Osmotic minipumps containing either A71623 (0.02mg/kg/day) were implanted intraperitoneally (i.p.)
Result:	Treatment dampened Purkinje neuron pathology in ATXN1[30Q]D776;Cck^-/- mice and ATXN1[82Q] mice. Improved motor performance in ATXN2[127Q] mice.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (59.46 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.1891 mL	5.9456 mL	11.8912 mL
5 mM	0.2378 mL	1.1891 mL	2.3782 mL
10 mM	0.1189 mL	0.5946 mL	1.1891 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture and light, under nitrogen